Royalty Pharma plc (NASDAQ:RPRX) Receives $41.67 Consensus PT from Analysts

Royalty Pharma plc (NASDAQ:RPRX) has been given a consensus recommendation of “Moderate Buy” by the six ratings firms that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $41.67.

Several brokerages recently issued reports on RPRX. Citigroup reduced their target price on shares of Royalty Pharma from $60.00 to $40.00 and set a “buy” rating for the company in a report on Friday, October 25th. StockNews.com upgraded Royalty Pharma from a “hold” rating to a “buy” rating in a research report on Tuesday, November 5th. Finally, The Goldman Sachs Group boosted their target price on shares of Royalty Pharma from $50.00 to $51.00 and gave the stock a “buy” rating in a research note on Wednesday, August 14th.

Institutional Investors Weigh In On Royalty Pharma

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Canada Pension Plan Investment Board raised its stake in shares of Royalty Pharma by 5.2% in the 1st quarter. Canada Pension Plan Investment Board now owns 923,639 shares of the biopharmaceutical company’s stock valued at $28,051,000 after acquiring an additional 45,839 shares during the period. BOKF NA lifted its stake in Royalty Pharma by 18.4% during the first quarter. BOKF NA now owns 18,280 shares of the biopharmaceutical company’s stock worth $547,000 after purchasing an additional 2,844 shares in the last quarter. B. Riley Wealth Advisors Inc. purchased a new position in shares of Royalty Pharma during the first quarter worth $487,000. California State Teachers Retirement System grew its stake in shares of Royalty Pharma by 2.1% in the first quarter. California State Teachers Retirement System now owns 649,055 shares of the biopharmaceutical company’s stock valued at $19,712,000 after buying an additional 13,533 shares in the last quarter. Finally, Tidal Investments LLC raised its holdings in shares of Royalty Pharma by 28.2% in the 1st quarter. Tidal Investments LLC now owns 90,149 shares of the biopharmaceutical company’s stock valued at $2,740,000 after buying an additional 19,834 shares during the period. Institutional investors and hedge funds own 54.35% of the company’s stock.

Royalty Pharma Stock Performance

RPRX opened at $26.47 on Friday. The company has a current ratio of 1.54, a quick ratio of 1.54 and a debt-to-equity ratio of 0.64. Royalty Pharma has a 12-month low of $25.10 and a 12-month high of $31.66. The firm has a 50 day moving average of $27.26 and a two-hundred day moving average of $27.36. The firm has a market capitalization of $15.60 billion, a PE ratio of 13.72, a P/E/G ratio of 4.64 and a beta of 0.47.

Royalty Pharma Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be issued a $0.21 dividend. This represents a $0.84 dividend on an annualized basis and a yield of 3.17%. The ex-dividend date of this dividend is Friday, November 15th. Royalty Pharma’s dividend payout ratio is presently 43.52%.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.